Corcept Therapeutics Inc. CORT

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

• Zacks Investment Research 2 oct

  4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

  With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.

  

• Zacks Investment Research 21 sept

  CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

  Corcept Therapeutics announced that the European Medicines Agency's CHMP committee issued a positive opinion recommending approval of Lifyorli (relacorilant) combined with nab-paclitaxel for platinum-resistant ovarian cancer treatment. The recommendation will be reviewed by the European Commission with a final decision expected in Q4 2026. Lifyorli generated $47.6 million in Q2 2026, its first quarter of commercial availability. The company is also studying relacorilant for other solid tumors and resubmitted an NDA for Cushing's syndrome treatment.

  

• The Motley Fool 12 jul

  Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook

  Corcept Therapeutics' Chief Development Officer William Guyer sold 20,000 shares worth $1.9 million on July 7, 2026, under a pre-scheduled Rule 10b5-1 trading plan established in November 2024. Despite liquidating 83% of his direct holdings, Guyer retains 130,000 stock options. The sale comes as Corcept achieved FDA approval for Lifyorli (cortisol-blocking ovarian cancer drug) ahead of schedule and raised full-year revenue guidance to $950 million-$1.05 billion, though the company posted a $31.8 million loss in Q1 due to heavy launch spending.